Consensus Celcuity Inc.

Stocks

CELC

US15102K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 07:00:00 31/10/26 am AEDT			5-day change	1st Jan Change
69.13 ^USD	-0.25%		+5.95%	-30.69%

24/10	Celcuity Inc. Presents Updated Results from the Pik3ca Mt Cohort of the Phase 3 Viktoria-1 Study in Patients with Hr+/Her2- Advanced Breast Cancer At the Esmo Congress 2026	CI
24/10	Celcuity Inc. Presents Updated Data From Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide In Men With Metastatic Castration-Resistant Prostate Cancer	CI

Evolution of the Average Target: Celcuity Inc.

Evolution of the Target Price: Celcuity Inc.

Changes in Analyst Recommendations: Celcuity Inc.

1dbbbf156bede95c02e56c07e1cca607.H_b0XyxSZah9EYng_YOumLLR7u-dR1uD9GqQXor-46M.d7SFCEsrP9sEQqSSs7LN-v-hw92rdzG6lgbjB-28ptJLooIlYicUzhxUvQ~6cce42dbb46251ce56c687e9b68dc44a

Analysts' recommendations: Celcuity Inc.

22/10	Cantor Fitzgerald Initiates Celcuity at Overweight With $140 Price Target	MT
17/09	JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target	MT
04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
04/05	HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94	MT
13/12	Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target	MT
18/11	Celcuity Shares Fall After HC Wainwright Downgrade	MT
17/11	HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77	MT
17/11	HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94	MT
13/11	Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share	RE
19/10/25	Celcuity Provides Update on Status of the Pik3ca Mutated Cohort of Phase 3 Viktoria-1 Trial and Releases Additional Data Analysis from Phase 1B Clinical Trial	CI
22/09/25	Guggenheim Initiates Celcuity at Buy With $110 Price Target	MT
27/08/24	LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target	MT
22/07/24	Leerink Partners Starts Celcuity With Outperform Rating, $29 Price Target	MT
31/05/24	Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating	MT
17/05/24	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating	MT
29/03/24	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT
28/03/24	Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating	MT
23/02/24	Stifel Initiates Celcuity With Buy Rating, Price Target is $40	MT
09/12/23	HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target	MT
18/05/22	Craig Hallum Adjusts Celcuity Price Target to $20 From $30, Maintains Buy Rating	MT
18/05/22	Needham Adjusts Celcuity's Price Target to $25 from $50, Keeps Buy Rating	MT
08/10/21	Celcuity : Canaccord Genuity Starts Celcuity at Buy With $50 Price Target	MT
07/09/21	Celcuity : Jefferies Starts Celcuity at Buy with $48 Price Target	MT
29/07/21	Celcuity : Cowen Initiates Coverage on Celcuity With Outperform Rating	MT
27/07/21	Celcuity : Needham Starts Celcuity at Buy With $50 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELCUITY INC.					+123.8%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+38.37%
	Weighted average by Cap.					+27.84%